Preliminary Calendar Year (CY) 2027 Medicare Clinical Laboratory Fee Schedule Payment Rates

A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.

Reassuring for GIP agonism. This seems to meet previous FDA CV safety standard ahead of CV outcomes trial. #tirzepatide https://t.co/cBo21QZmiy https://t.co/SRvuoPegE6

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.

YouTube video by Ann Marie Navar

Our reanalysis of the randomized control trial data using Egger regression adds to the existing evidence that the cardiovascular benefits of statins and their association with incident diabetes mellitus are mediated primarily, if not entirely, via their LDL-C lowering properties rather than by any p …

Recent research suggests that more people should be screened for a protein called apoB. A growing number of doctors agree.

Nature Reviews Cardiology, Published online: 23 January 2026; doi:10.1038/s41569-026-01249-zIn this Review, Galli and colleagues discuss the mechanisms and associated biomarkers of traditional and emerging factors responsible for the residual risk of recurrent adverse cardiovascular events in patients with coronary artery disease, with a focus on new pathophysiological insights and the therapeutic implications.

In my first blog, I expressed skepticism about using additional blood tests for cardiovascular disease (CVD) risk prediction beyond traditional risk factors.

NephJC short on an empagliflozin meta-analysis

This study suggests that ApoB is a more accurate marker for cardiovascular risk than LDL-P when discordant, as marked by ApoB levels in excess of LDL-P. Notably, risk was already elevated at as little...